The Navigator Company (NVG) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
27 May, 2026Executive summary
Q1 2026 was marked by heightened geopolitical instability and severe weather in Portugal, causing operational disruptions, higher costs, and supply chain challenges.
Diversification, especially in Tissue and Packaging, supported resilience, with these segments contributing nearly 40% of EBITDA.
Price increases across all segments reversed a six-quarter downward trend in key paper indices.
Strategic initiatives included new product launches, partnerships, and capacity expansions, particularly in tissue and packaging.
Turnover reached €427 million, down 11% sequentially and 19% YoY; EBITDA was €65 million, down 14% sequentially and 44% YoY.
Financial highlights
Revenue was €426.8 million, down 11.2% from Q4 2025 and 19.4% YoY.
EBITDA was €64.8 million, margin at 15.2%, down 14.1% sequentially and 43.9% YoY.
Net profit was €17.2 million, down 64% YoY.
Free cash flow was €28.2 million, down 51% YoY.
CapEx reached €42.4 million, with 53% allocated to sustainability and ESG projects.
Outlook and guidance
Pulp prices expected to remain above 2025 levels, with further increases in Europe until Q3 and in China until Q2, followed by moderate corrections.
No significant new supply expected until 2027-2028, supporting a favorable supply-demand balance.
Multi-stage price increases underway in printing, writing, tissue, and packaging papers across all key markets.
Q2 average prices anticipated to be higher than Q1 as operational constraints ease.
Tissue demand remains resilient, with annual growth estimated at 1.1%.
Latest events from The Navigator Company
- Diversification into tissue and packaging offset profit declines amid challenging market conditions.NVG
Q4 202513 Apr 2026 - Record H1 2024: 9% revenue growth, 28% EBITDA margin, robust tissue gains, top ESG ranking.NVG
H1 20242 Feb 2026 - Turnover, EBITDA, and net profit rose double digits, led by tissue and packaging growth.NVG
Q3 202417 Jan 2026 - Turnover up 7% to €2.09B, EBITDA at €547M, net profit up 4%, and €175M dividend proposed.NVG
Q4 202416 Dec 2025 - Q1 2025 saw resilient growth, strong tissue and packaging, and stable margins.NVG
Q1 202519 Nov 2025 - Tissue and Packaging offset profit declines, with cost controls and sustainability investments supporting resilience.NVG
Q3 202531 Oct 2025 - Tissue and Packaging growth offset profit declines, with resilience amid global volatility.NVG
Q2 202530 Oct 2025